EU CHMP recommends approval of Trimbow (beclometasone dipropionate + formoterol fumarate + glycopyrronium) in COPD- Chiesi

The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Trimbow (beclometasone dipropionate + formoterol fumarate + glycopyrronium), from Chiesi, intended for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD). Trimbow is a triple combination of an inhaled glucocorticoid (beclometasone dipropionate), a long-acting beta2 receptor agonist (formoterol fumarate dihydrate) and a long-acting muscarinic antagonist (glycopyrronium bromide). It will be available as a pressurised metered dose inhaler delivering a solution with a nominal dose per actuation of 87 micrograms / 5 micrograms / 9 micrograms of the active substances respectively.

The benefits with Trimbow are its ability to relieve and prevent symptoms such as shortness of breath, wheezing and cough and to reduce exacerbations of COPD symptoms. The most common side effects of Trimbow are oral candidiasis, muscle spasm and dry mouth.